Observational database for patients with immune thrombocytopenia in Brest

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to create a comprehensive clinical and biological database for patients diagnosed, treated, and followed for immune thrombocytopenia (ITP) at the University Hospital of Brest. By collecting detailed information on patient demographics, treatment regimens, and clinical outcomes, the study seeks to enhance understanding of ITP and improve patient management. The University Hospital of Brest serves as a regional reference center for hemorrhagic diseases, ensuring a focused approach to this condition. The data collected will be invaluable for future research and treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with ITP agree to participate

Exclusion Criteria:

* Other thrombocythopenia other than ITP
* Patients Under guardianship
* Patients without national social security

Where it's running

• Hematology Department - Institute of Oncology and Hematology, University Hospital of Brest
  Brest, Brittany Region, France Recruiting

Study contacts

• Principal investigator: Brigitte Pan-Petesch, MD — Uhb
• Study coordinator: Brigitte Pan-Petesch, MD
• Email: brigitte.pan-petesch@chu-brest.fr
• Phone: 33298223650

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

• GL-2045 safety and blood-count help for adults with ITP

  GL-2045 is being tested in adults with immune thrombocytopenia to see if it can safely raise platelet counts like IVIg does.

  Recruiting Phase 1 Gliknik Inc. · Leeds · NCT07605845

• Eltrombopag use in adults with primary ITP: real-world patterns and outcomes

  This study looks at how eltrombopag is used in adult patients with primary ITP and what outcomes are seen in routine care.

  Recruiting Novartis · Basel · NCT07587723

• Daratumumab versus rituximab for children with primary immune thrombocytopenia

  This study will test whether daratumumab works better than rituximab to increase platelet counts in children aged 6–17 with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07362238

• Daratumumab plus rituximab for adults with relapsed or refractory immune thrombocytopenia

  This treatment combines daratumumab (an anti‑CD38 antibody) with rituximab to see if it raises platelet counts in adults with ITP who haven't responded to steroids and other therapies.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07362199

• Daratumumab versus rituximab for adult primary immune thrombocytopenia

  This trial will test whether daratumumab (an anti‑CD38 antibody) works better than rituximab for adults with primary ITP who did not respond to or relapsed after steroid treatment.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07297563

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.